MetaVia Inc. MTVA 深 滬
等待開盤 04-03 09:30:00 美东时间
1.26
+0.010
+0.80%
華盛通- 最 高1.29
- 今 開1.24
- 成交量 5.25万股
- 最 低 1.20
- 昨 收 1.25
- 總市值 641.46万
- 52周最高 23.10
- 市盈率 靜 --
- 換手率 1.03%
- 52周最低 1.17
- 委 比 44.82%
- 總股本 509.09万
- 歷史最高 1527900.00
- 量 比 0.66
- 振 幅 7.20%
- 歷史最低 1.17
- 每 手 1
- 風險率 3.61%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 能源股再或大行青睐！康菲石油、雪铁龙、埃克森美孚、响尾蛇能源等获上调目标价；Unity评级分歧大，大摩、美银上调，富国银行下调
今日重点评级关注：花旗：维持Biomea Fusion"买入"评级，目标价从6美元升至7美元；Chardan Capital：维持Hyperion DeFi"买入"评级，目标价从7.75美元升至8.25美元
03-30 11:49
HC Wainwright & Co. Maintains Buy on MetaVia, Lowers Price Target to $20
HC Wainwright & Co. analyst Andrew S. Fein maintains MetaVia (NASDAQ:MTVA) with a Buy and lowers the price target from $40 to $20.
03-28 00:27
MetaVia Q4 EPS $(0.42) Beats $(1.73) Estimate
MetaVia (NASDAQ:MTVA) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(1.73) by 75.69 percent. This is a 88.07 percent increase over losses of $(3.52) per share from the same
03-26 20:37
MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update
48 mg Phase 1 Data Demonstrate Potential Best-in-Class Profile for DA-1726 with 9.1% Weight Loss, Improved Glucose Control and Direct Liver Benefit Planned Phase 1 Part 3 16-Week Titration S...
03-26 20:31
Institutional Review Board At Clinical Pharmacology Of Miami Approves MetaVia Phase 1 Part 3 Clinical Trial Of DA-1726.
16-Week Study to Evaluate One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obese Otherwise Healthy Adults
03-18 20:13
MetaVia Announces Global IP Portfolio Supporting Vanoglipel
MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a comprehensive global intellectual property portfolio supporting vanoglipel
03-12 21:08
MetaVia CEO Hyung Heon Kim to Join Life Sciences Virtual Investor Forum Fireside Chat
MetaVia CEO Hyung Heon Kim to Join Life Sciences Virtual Investor Forum Fireside Chat MetaVia Inc. said its President and CEO Hyung Heon Kim will join a fireside chat at the Life Sciences Virtual Investor Forum, co-hosted by Zacks Small Cap Research, on March 12, 2026 at 10:30 a.m. ET. Investors can
03-04 21:31
MetaVia Inc. Publishes Investor Presentation on Obesity and MASH Drug Pipeline
MetaVia Inc. Publishes Investor Presentation on Obesity and MASH Drug Pipeline MetaVia Inc. (Nasdaq: MTVA) released an investor presentation outlining its clinical-stage pipeline focused on obesity and metabolic dysfunction-associated steatohepatitis (MASH). The company highlighted DA-1726, a once-w
02-24 09:26
MetaVia Announces Global IP Portfolio Supporting DA-1726, Dual OXM Analog Agonist That Functions As GLP1R And GCGR, For Treatment Of Obesity And Related Metabolic Disorders
Intellectual Property Portfolio Includes 39 Granted and Pending Patents in the U.S. and Internationally, Providing Protection Into 2041, Unless Extended FurtherCAMBRIDGE, Mass., Feb. 13, 2026 /PRNewswire/ -- MetaVia Inc.
02-13 21:35
MetaVia Inc. Secures Global Patent Protection for DA-1726 Obesity Therapy Through 2041
MetaVia Inc. Secures Global Patent Protection for DA-1726 Obesity Therapy Through 2041 MetaVia Inc. announced it has secured comprehensive global patent protection for its lead asset DA-1726, a dual oxyntomodulin analog agonist for the treatment of obesity and related metabolic disorders. The intell
02-13 21:31
